LSC
DMAA

Logan Stone Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Logan Stone Capital’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,900
Closed -$113K – 188
2025
Q4 		$113K Buy
+10,900
New +$113K 0.03% 146
2025
Q3 		– Sell
-60,991
Closed -$622K – 96
2025
Q2 		$622K Buy
+60,991
New +$617K 0.29% 46

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.22% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Logan Stone Capital's DMAA Position: Q1 2026 in Review

Logan Stone Capital sold out of Drugs Made In America Acquisition Corp (DMAA) in Q1 2026, closing a stake of 10,900 shares — an estimated $113K sold.

Logan Stone Capital first reported a position in DMAA in Q2 2025 and held it in 2 quarters. The position peaked at $622K in Q2 2025. 39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • Logan Stone Capital reported no remaining Drugs Made In America Acquisition Corp position as of Q1 2026 after selling out during the quarter.
  • Logan Stone Capital sold 10,900 Drugs Made In America Acquisition Corp shares in Q1 2026, an estimated $113K.
  • Logan Stone Capital first reported a position in Drugs Made In America Acquisition Corp in Q2 2025 and held it in 2 quarters.
  • Logan Stone Capital's Drugs Made In America Acquisition Corp position peaked at $622K in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on Logan Stone Capital's 13F filing for Q1 2026, filed 15 May 2026.